Given the recent voting deadline for Johnson & Johnson's proposed $6.48 billion talc litigation settlement, what is the probability that the company successfully reaches the 75% claimant approval threshold required to pursue a third 'Texas Two-Step' bankruptcy filing to resolve all current and future ovarian cancer claims?

Context & Scope As of March 2026, the timeline regarding Johnson & Johnson’s (J&J) third attempt to resolve its talc-related ovarian cancer liabilities via a "Texas Two-Step" bankruptcy has fully concluded. Consequently, the probability of the company reaching the required 75% claimant approval threshold is no longer a forward-looking estimate, as the voting phase was completed in late 2024. However, achieving this threshold did not translate into a successful bankruptcy resolution. Core Analysis: The Vote and Subsequent Bankruptcy Failure 1. Achievement of the Voting Threshold In August 2024, J&J successfully secured the requisite 75% claimant approval for its initial $6.48B settlement proposal. This supermajority vote was the statutory prerequisite needed to file a prepackaged Chapter 11 bankruptcy for its subsidiary, Red River Talc, in a Texas federal court. 2. The Third Bankruptcy Attempt Following the successful vote, J&J proceeded with its third bankruptcy filing. During the proceedings, the company increased its settlement offer to approximately $8B (with some structural valuations reaching $9B ) to be paid out over 25 years. The strategic intent was to permanently cap liabilities and channel all current and future ovarian cancer claims into a single bankruptcy trust. 3. Judicial Dismissal (April 2025) Despite securing the necessary claimant votes, the strategy ultimately failed. In April 2025, U.S. Bankruptcy Judge Christopher Lopez formally rejected the settlement and dismissed the Chapter 11 case. The dismissal was predicated on two primary legal flaws: Voting Irregularities: The court found the 75% approval vote to be compromised. Irregularities included claimants being given insufficient time to review the terms, unauthorized voting by plaintiff law firms on behalf of clients, and improperly switched votes. Invalid Third-Party Releases: The judge ruled that the bankruptcy plan improperly attempted to shield non-bankrupt entities (such as J&J’s parent company and its consumer health spin-off, Kenvue) from liability. This decision heavily cited the Supreme Court’s precedent in the Purdue Pharma case, which restricted the use of non-consensual third-party releases in bankruptcy courts. Risks, Limitations, and Financial Implications With the dismissal of the third bankruptcy attempt, J&J confirmed it would not appeal the April 2025 ruling, effectively abandoning the "Texas Two-Step" strategy for these claims. Reversion to Tort Litigation: J&J now faces the prospect of litigating or individually settling more than 61,000 pending ovarian cancer lawsuits through state courts and federal multidistrict litigation (MDL). Uncapped Financial Exposure: The failure to cap liabilities at $8B reintroduces significant, long-tail financial uncertainty. Historically, individual and consolidated jury trials have resulted in severe punitive damages, including a landmark $2.12B verdict in Missouri and a $45M verdict in Illinois. Balance Sheet Resilience: While the legal setbacks represent a material headwind, J&J’s broader financial position remains highly capitalized. The company generates substantial free cash flow from its pharmaceutical and medical device divisions, which appears sufficient to absorb ongoing legal costs, albeit with a persistent drag on overall valuation multiples. Summary Conclusion The probability that J&J reached the 75% claimant approval threshold was realized at 100% in August 2024. However, due to the April 2025 judicial dismissal of the bankruptcy filing, the probability of the company successfully utilizing this vote to execute a third "Texas Two-Step" bankruptcy and permanently resolve its talc liabilities is definitively 0% .

As Johnson & Johnson prepares for the early 2025 entry of U.S. biosimilars for Stelara, how do current clinical trial readouts for Tremfya in IBD and the ramp-up of the oncology franchise influence the company's ability to maintain its 5% to 7% operational sales growth target through 2030?

Context & Scope Johnson & Johnson (JNJ) is currently navigating one of its most significant patent cliffs with the early 2025 U.S. loss of exclusivity (LOE) for its blockbuster immunology drug, Stelara. Despite this structural headwind, JNJ management has maintained a commitment to a 5% to 7% operational sales Compound Annual Growth Rate (CAGR) through 2030. As of early 2026, assessing the viability of this target requires analyzing how the company is offsetting Stelara's decline. The core of this transition relies on two strategic pillars: the successful migration of its Inflammatory Bowel Disease (IBD) franchise to Tremfya (guselkumab) and the aggressive, double-digit expansion of its oncology portfolio. The Stelara Patent Cliff & Biosimilar Impact Stelara has historically been JNJ’s top-selling asset, generating $10.4B in 2024. The introduction of U.S. biosimilars in early 2025 triggered a fierce pricing war driven by Pharmacy Benefit Managers (PBMs) and private label strategies. Revenue Contraction: The aggressive adoption of biosimilars resulted in a severe -42.7% decline in Stelara sales over the course of 2025. Strategic Shift: To prevent this from derailing the enterprise-wide growth target, JNJ required immediate and substantial revenue offsets from its next-generation immunology assets and its broader Innovative Medicine division. Immunology Defense: Tremfya’s IBD Clinical Readouts To defend its market share in gastroenterology, JNJ has strategically positioned Tremfya (an IL-23 inhibitor) as the superior successor to Stelara. Recent clinical trial readouts and subsequent FDA approvals have been critical in bridging the revenue gap: Crohn's Disease (GALAXI Study): In March 2025, Tremfya received FDA approval for Crohn's disease. Crucially, data from the Phase 3 GALAXI registrational study demonstrated Tremfya's superiority over Stelara across all pooled endoscopic endpoints. This head-to-head clinical superiority is vital for migrating patients away from cheaper Stelara biosimilars to a premium, patent-protected asset. Ulcerative Colitis (QUASAR & ASTRO Studies): Following its late-2024 approval for Ulcerative Colitis (UC) based on the QUASAR program, JNJ submitted supplemental data (ASTRO study) for a subcutaneous induction regimen. The ability to offer both intravenous and fully subcutaneous induction options provides a competitive edge in patient convenience and adherence. Growth Implication: By proving superior efficacy and endoscopic remission rates, Tremfya appears to be successfully capturing the IBD market share that Stelara is shedding, thereby stabilizing the immunology franchise's baseline revenue and preventing a prolonged contraction. Oncology Franchise: The Primary Growth Engine While Tremfya plays defense in immunology, JNJ’s oncology franchise is playing aggressive offense, serving as the primary engine to achieve the 5% to 7% enterprise growth target. Revenue Acceleration: In late 2025, the oncology division drove nearly 20% revenue gains, pushing the overall Innovative Medicine segment to a 10% quarterly growth rate ( $15.76B in Q4 2025). This over-performance directly offset the Stelara declines. Key Assets: Growth is anchored by established blockbusters like Darzalex and rapidly scaling advanced therapies like the CAR-T cell therapy Carvykti, which recently surpassed the $1B sales milestone. 2030 Outlook: JNJ management has outlined a highly optimistic trajectory for oncology, projecting the franchise will generate between $40B and $50B in annual sales by 2030. This represents a massive Total Addressable Market (TAM) capture that fundamentally alters JNJ's revenue mix. Synthesis: Viability of the 2025–2030 Growth Target The interplay between Tremfya's clinical success and the oncology ramp-up has validated JNJ's growth model. As of January 2026, JNJ raised its full-year 2026 revenue guidance to a range of $99.5B to $100.5B , up from $94.2B in 2025. Funding the Transition: JNJ is executing a classic pharmaceutical playbook: using a hyper-growth segment (Oncology) to fund the transition away from a declining one (Stelara), while simultaneously launching a superior successor (Tremfya) to retain therapeutic area dominance. Target Feasibility: The clinical superiority of Tremfya in IBD ensures the immunology floor does not collapse, while the sheer scale of the oncology pipeline provides the necessary upward thrust. Together, these factors make the 5% to 7% operational CAGR through 2030 highly credible, provided execution remains consistent. Key Risks & Uncertainties Despite the strong 2026 outlook, several risks could pressure the long-term growth target: Biosimilar Pricing Dynamics: The PBM-driven pricing war for Stelara biosimilars could accelerate price erosion faster than Tremfya can capture new patient starts, potentially compressing immunology margins. Macro Pricing Pressures: JNJ recently had to absorb over $450M in costs related to U.S. drug pricing deals, highlighting ongoing regulatory and legislative risks to pharmaceutical profitability. Execution Risk in Oncology: The $40B+ oncology target relies heavily on the flawless commercial scaling of complex therapies like Carvykti and the successful launch of upcoming pipeline assets. Manufacturing bottlenecks or clinical setbacks could jeopardize this trajectory.

Following the recent $13.1 billion acquisition of Shockwave Medical, how will the integration of intravascular lithotripsy technology impact Johnson & Johnson's MedTech margins and its competitive positioning in the high-growth interventional cardio-vascular market relative to peers like Boston Scientific?

Executive Overview Johnson & Johnson’s (J&J) $13.1B acquisition of Shockwave Medical, completed in 2024, represents a transformative structural shift in its MedTech portfolio. By integrating Shockwave’s proprietary Intravascular Lithotripsy (IVL) technology, J&J secured a near-monopoly in a highly disruptive segment of cardiovascular calcium modification. As of early 2026, this integration appears to be a primary catalyst for J&J’s MedTech margin expansion and significantly alters the competitive dynamics in the interventional cardiovascular space, directly challenging entrenched incumbents like Boston Scientific. Financial & Margin Implications The financial architecture of the Shockwave acquisition was designed to structurally elevate J&J’s MedTech profitability, despite short-term financing headwinds. Gross Margin Accretion: Prior to the acquisition, Shockwave consistently reported exceptional gross margins of approximately 87% to 88% . Integrating a product line with such high profitability is structurally accretive to J&J’s overall MedTech operating margins, shifting the division's revenue mix toward higher-margin, premium consumables. Revenue Growth & Platform Scale: Shockwave was designated as J&J MedTech’s 13th priority platform—a category reserved for assets generating over $1B in annual sales. By the end of 2025, J&J’s cardiovascular segment was the only MedTech unit to post double-digit year-over-year growth, heavily fueled by the integration of Shockwave alongside its electrophysiology and Abiomed units. EPS Dilution vs. Operational Accretion: While the transaction was immediately accretive to operating margins, the debt financing required for the $13.1B purchase resulted in short-term adjusted EPS dilution of approximately -$0.10 in 2024 and -$0.17 in 2025. Moving into 2026, the operational leverage of the combined entity is expected to begin outpacing these financing costs. Competitive Positioning: J&J vs. Boston Scientific Boston Scientific remains a dominant force in interventional cardiology and peripheral vascular devices, holding an estimated 18% global market share in 2025. However, J&J’s acquisition of Shockwave fundamentally changes the competitive landscape in the specific, high-growth niche of calcified lesion modification. 1. Technological Differentiation (IVL vs. Atherectomy) Boston Scientific’s calcium modification portfolio relies heavily on Rotational Atherectomy (e.g., the Rotablator/RotaPro systems). Atherectomy uses a high-speed diamond-coated burr to physically shave or sand calcium. While highly effective for uncrossable, tight lesions, it carries a steeper learning curve and higher risks of procedural complications, such as dissections or perforations. Conversely, Shockwave’s IVL uses sonic pressure waves to fracture calcium from within the vessel wall. It is balloon-deliverable, easier for physicians to adopt, and generally presents a safer profile for concentric, thick calcium. Because IVL does not require complex guidewire exchanges, it reduces procedural time—a critical metric for catheterization lab efficiency. 2. Ecosystem Synergies in the Cath Lab J&J is aggressively building a comprehensive "cath lab of the future." By combining Shockwave (IVL) with Abiomed (Impella heart pumps for hemodynamic support during complex percutaneous coronary interventions) and Biosense Webster (electrophysiology), J&J offers a highly synergistic suite of premium cardiovascular tools. This ecosystem approach allows J&J to cross-sell and bundle contracts, potentially eroding Boston Scientific’s traditional stronghold in hospital purchasing agreements. 3. Complementary vs. Cannibalistic Dynamics It is worth noting that IVL and atherectomy are not strictly mutually exclusive. In severely calcified, uncrossable lesions, physicians may use Boston Scientific's atherectomy to open the vessel, followed by J&J's IVL to fracture deep calcium (a technique sometimes referred to in clinical practice as "Rota-Tripsy"). However, for a significant portion of standard calcified lesions, IVL is increasingly becoming the first-line therapy, capturing market share from traditional atherectomy and specialty cutting balloons. Key Risks & Uncertainties While the strategic rationale is sound, J&J's positioning faces several forward-looking risks: Competitive Response: Boston Scientific, Medtronic, and Abbott are heavily investing in R&D. The potential development of alternative lithotripsy devices, next-generation atherectomy tools, or advanced intravascular imaging integrations could eventually challenge Shockwave’s current technological moat. Reimbursement Dynamics: The premium pricing of IVL catheters relies on favorable reimbursement codes (such as transitional pass-through payments or specific DRG assignments). Any downward pressure on Medicare or private insurance reimbursement rates could compress the 87% gross margins that made the asset so attractive. Integration and Execution: Realizing the full synergies of a $13.1B acquisition requires flawless commercial execution, particularly in international markets where Boston Scientific has deeply entrenched clinician relationships and established supply chains.

Johnson & Johnson (JNJ) Stock Price & AI Analysis

GoAI Score

Sign in to unlock

Valuation

50Fair Value

Sentiment

50Neutral

Risk

100Low Risk

Momentum

79Positive

Institutional-Grade Intelligence

🏆PRO

Actionable Intelligence

AI-driven stance, execution logic & risk thresholds

Catalyst Roadmap

Event timeline with expected impact & market context

Deep Insights

Fact-checked analysis & score logic breakdown

Financial Statements

Margin Trends

Gross

72.8%▲3.7pp

Revenue after COGS

Operating

27.2%▲2.2pp

After operating expenses

Net

28.5%▲12.6pp

Bottom-line profitability

Gross Margin

Operating Margin

Net Margin

Valuation Snapshot

P/E Ratio

18.8

Price vs earnings

EV/EBITDA

13.3

Enterprise value

FCF Yield

3.9%

Cash generation

Earnings Yield

5.3%

Inverse of P/E

Capital Efficiency

19

GoAI Quality ScoreStrong

ROEReturn on Equity

32.9%Strong

ROAReturn on Assets

13.5%Strong

ROICReturn on Invested Capital

13.7%Strong

Financial Health

Current RatioAdequate

1.03

Short-term solvency (>1.5)

Net Debt / EBITDAManageable

0.71x

Debt repayment capacity (<3x)

Income QualityFair

0.92

Cash backs earnings (>1)

Revenue & Profitability

Revenue

Net Income

Net Loss

Income Statement

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$94.19B	$88.82B	$85.16B	$79.99B	$78.74B
Gross Profit	$68.56B	$61.35B	$58.61B	$55.39B	$55.34B
Gross Margin	72.8%	69.1%	68.8%	69.3%	70.3%
Operating Income	$25.60B	$22.15B	$23.41B	$21.01B	$20.94B
Net Income	$26.80B	$14.07B	$35.15B	$17.94B	$20.88B
Net Margin	28.5%	15.8%	41.3%	22.4%	26.5%
EPS	$11.03	$5.84	$13.88	$6.83	$7.93

Average Price Target

$228.73▼ 2.8% Downside

Past 12 Months

12 Month Forecast

Based on 50 Wall Street analysts offering 12 month price targets for Johnson & Johnson, the average price target is $228.73, with a high forecast of $265.00 and a low forecast of $190.00. The average price target represents a 2.8% decrease from the current price of $235.27.

Highest

$265.00

Average

$228.73

Lowest

$190.00

Rating Distribution

Strong Buy

0

0%

Buy

20

51%

Hold

16

41%

Sell

3

8%

Strong Sell

0

0%

Recent Analyst Ratings

FirmActionRatingDate

Barclays● Maintain

Equal Weight

2026-03-19

HSBC● Maintain

Buy

2026-03-17

Citigroup● Maintain

Buy

2026-03-11

JP Morgan● Maintain

Neutral

2026-03-05

RBC Capital● Maintain

Outperform

2026-02-03

Morgan Stanley▲ Upgrade

Equal Weight→Overweight

2026-01-28

Freedom Capital Markets● Maintain

Hold

2026-01-27

Guggenheim● Maintain

Buy

2026-01-23

Scotiabank● Maintain

Sector Outperform

2026-01-22

Morgan Stanley● Maintain

Equal Weight

2026-01-22

Earnings History & Surprises

BEAT RATE

94%

Last 18 quarters

AVG SURPRISE

+4.1%

EPS vs Estimate

BEATS / MISSES

17/0

1 met exactly

LATEST EPS

$2.46

Q1 '26

QUARTERLY EPS TREND

Estimated

Beat

Miss

QUARTERLY DETAIL

Q1 '26

$2.46 vs $2.46

Q4 '25

+1.4%

$2.80 vs $2.76

Q3 '25

+3.4%

$2.77 vs $2.68

Q2 '25

+7.4%

$2.77 vs $2.58

Q1 '25

+2.5%

$2.04 vs $1.99

Q4 '24

+9.5%

$2.42 vs $2.21

Q3 '24

+4.1%

$2.82 vs $2.71

Q2 '24

+2.7%

$2.71 vs $2.64

Q1 '24

+0.9%

$2.29 vs $2.27

Q4 '23

+5.6%

$2.66 vs $2.52

Q3 '23

+7.3%

$2.80 vs $2.61

Q2 '23

+6.8%

$2.68 vs $2.51

Investor Q&A

Top questions investors are asking about Johnson & Johnson

3 Questions

Ask GoAI anything about Johnson & Johnson

Latest News

No news available